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INTRODUCTION
Perineal trauma can occur spontaneously or as a result of ob-
stetric interventions, such as an episiotomy or operative vagi-
nal delivery.1,2 The reported incidence of perineal trauma dur-
ing vaginal delivery is approximately 85%, but can vary in 
different settings, depending on clinical practice and condi-
tions during vaginal delivery.2 Anal sphincter injuries, which 
are the most severe perineal trauma events, have gradually in-
creased in number over the last several decades, with incidence 
rates ranging from 4.1% to 16.0% in several population-based 
studies.3,4 Perineal trauma during vaginal delivery has been 
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Purpose: Hyaluronidase (HAase) has many uses in medicine, and reports suggest that it affects perineal tissue during fetal passage 
through the vaginal canal. However, its potential use for preventing perineal trauma has yet to be determined. This study sought to 
evaluate the efficacy and safety of perineal HAase injections in reducing perineal trauma during vaginal delivery. 
Materials and Methods: A multi-center, double-blind, placebo-controlled, randomized study was conducted from January 2016 to 
March 2017. Nulliparous women who planned to undergo vaginal delivery were recruited, and the enrolled women were random-
ly assigned to the HAase injection group (HAase injection, 5000 IU, n=75) or the control group (normal saline injection, n=73). The 
degree of perineal laceration, rate of episiotomy, and grade of perineal edema at 1 hour and 24 hours after spontaneous vaginal de-
livery were compared between the two groups.
Results: A total of 148 women who underwent vaginal delivery were recruited. No significant differences were observed between 
the HAase injection and control groups in the rates of perineal laceration (p=0.422). Perineal edema significantly decreased 24 
hours after delivery in the women treated with perineal HAase injections, compared to women in the control group (p=0.008). The 
overall incidences of adverse events, such as redness of the injection site, infection, and wound dehiscence, were similar between 
the two groups. 
Conclusion: HAase injections in nulliparous women afforded no reductions in the rates of perineal lacerations and episiotomy. 
However, the use of perineal HAase injections did reduce perineal edema without severe adverse events.
Key Words:  Vaginal delivery, nulliparity, perineal trauma, hyaluronidase, randomized controlled trial
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: July 23, 2019   Revised: November 13, 2019
Accepted: November 19, 2019
Corresponding author: Gyu Yeon Choi, MD, PhD, Department of Obstetrics and 
Gynecology, Soonchunhyang University Seoul Hospital, 59 Daesagwan-ro, Yongsan-
gu, Seoul 04401, Korea.
Tel: 82-2-709-9324, Fax: 82-2-709-9932, E-mail: kychoi@schmc.ac.kr
The data in this study were presented at the 7th Japan-Korean-Taiwan Symposium 
on Maternal-Fetal Medicine, which was held in Takamatsu, Japan on August 25, 2017.
•The authors have no potential conflicts of interest to disclose.
© Copyright: Yonsei University College of Medicine 2020
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (https://creativecommons.org/licenses/
by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2020 Jan;61(1):79-84
https://doi.org/10.3349/ymj.2020.61.1.79
80
Hyaluronidase for Preventing Perineal Trauma
https://doi.org/10.3349/ymj.2020.61.1.79
shown to be associated with significant maternal morbidities, 
including blood loss, perineal pain, infection, dyspareunia, uri-
nary incontinence, flatus, and fecal incontinence, and to lead 
to the development of comorbidities, including sexual dys-
function, pelvic organ prolapse, and rectovaginal and vesico-
vaginal fistulas.3,5,6 Thus, the prevention of perineal trauma is 
important because its associated morbidities have a profound 
effect on both the physical and psychological well-being of the 
mother, which may result in social isolation and the marginal-
ization of those with ongoing morbidity.7
Hyaluronidase (HAase) is an enzymatic complex that depo-
lymerizes and hydrolyzes hyaluronic acid, which reduces the 
viscosity of hyaluronic acid and improves both tissue diffusion 
and the resorption rate of excess fluids.8,9 HAase is involved in 
several physiological and pathological reactions and, there-
fore, has been utilized in various fields of medicine, such as 
fertilization,10 wound healing,11 ophthalmic surgery,12 and local 
anesthesia.13 During the 1950s and 1960s, HAase was used to 
prevent perineal trauma and to reduce the need for an episiot-
omy.14-22 Some studies have suggested a beneficial effect for 
perineal HAase injections during spontaneous vaginal deliv-
ery: HAase injections reduced the frequency of episiotomy 
and severe perineal lacerations (third- or fourth-degree peri-
neal lacerations) and increased the frequency of an intact 
perineum following delivery.21,22 However, no difference in the 
incidences of episiotomy and severe perineal lacerations has 
been reported in randomized trials.22,23 Although HAase is com-
monly used in clinical practice, its potential use as a method to 
prevent perineal trauma is controversial. Therefore, we aimed 
to evaluate whether perineal HAase injections during vaginal 
deliveries reduce perineal trauma in nulliparous women. 
MATERIALS AND METHODS
Study design and participants
This multi-center, double-blind, placebo-controlled, random-
ized study included women undergoing vaginal delivery from 
January 2016 to March 2017 at five university-based clinical 
centers in Korea. Inclusion criteria were a maternal age between 
19 and 40 years, gestational age between 37 weeks, 0 days and 
41 weeks, 6 days, nulliparous women with no previous record 
of vaginal birth, vertex presentation, and singleton pregnancy. 
Exclusion criteria were multifetal gestations, non-vertex pre-
sentation, fetal congenital anomaly, estimated birth weight 
≥4000 g, abnormal placental implantation, hypersensitivity to 
HAase, and women in whom vaginal delivery was not feasible. 
Eligible women were randomly assigned to one of two groups 
(HAase injection and control group) using a permuted block 
randomization method previously generated by a statistician. 
To calculate the sample size, we presumed that the frequency 
of perineal injuries greater than or equal to first-degree lacera-
tions in women without HAase treatment was 75.7%.15 If the 
same number of women were enrolled in the study and con-
trol groups, 73 women were needed in each group to detect a 
31% risk reduction in perineal injury, with a type I error rate of 
5% and a power of 80%.24 Therefore, considering a drop-out 
rate of 20%, we enrolled 184 women.
Procedures and perineal management
The HAase injection group was injected with 3 mL of 5000 IU 
HAase (Hirax®, BMI Korea, Seoul, Korea) mixed with 3 mL of 
1% lidocaine hydrochloride solution, and the control group 
was treated with a combination of 3 mL of normal saline and 
3 mL of 1% lidocaine hydrochloride solution. They received in-
jections with their treatment solutions in the perineal subcuta-
neous tissue at the center and in the left and right of the perine-
um within 1 hour before fetal expulsion through the vagina. An 
episiotomy was performed upon each clinician’s judgment 
with indications including a rigid perineum or fetal distress. 
Study outcomes
Data were collected during labor and at 1 hour and 24 hours 
after delivery. All deliveries and postpartum evaluations were 
conducted by one of the authors according to the research 
protocol and described procedures. 
The primary outcomes were perineal lacerations (greater 
than or equal to a first-degree laceration). Secondary outcomes 
were perineal edema and episiotomy. Perineal laceration was 
classified according to the classification originally described 
by Sultan and Fernando25: 1) a first-degree laceration is that of 
either the vaginal epithelium or perineal skin only; 2) a second-
degree laceration involves the perineal muscles, but not the 
anal sphincter; 3) a third-degree laceration exhibits disruption 
of the anal sphincter muscles; and 4) a fourth-degree lacera-
tion is a third-degree tear with disruption of the anal epitheli-
um. Severe perineal lacerations were defined as third- and 
fourth-degree lacerations. If an episiotomy was performed and 
no evidence of a third- or fourth-degree lacerations was ob-
served, the event was categorized as a first- or a second-degree 
laceration. Perineal edema was identified by the application of 
pressure to the swollen skin of the perineum with a finger and 
categorized into five grades: 1) Grade 0 showed no change in 
pre-delivery contour; 2) Grade 1 had mild pitting and slight in-
dentation with a depth within 2 mm; 3) Grade 2 had moderate 
pitting edema, and the indentation subsided rapidly (10–15 
seconds) with a depth of 4 mm; 4) Grade 3 had deep pitting, 
and the indentation remained for a short time (about 1 minute) 
with a depth of 6 mm and appeared swollen; and 5) Grade 4 
had deep pitting, the indentation subsided over 2–5 minutes 
with a depth of about 8 mm, and the perineum was very swol-
len.26 Perineal edema was evaluated at 1 hour and 24 hours 
after delivery. Information on side effects, such as fever, infec-
tion, and pain, were evaluated in both groups to determine the 
safety of HAase.
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Statistical analysis
Analyses were performed according to the intention-to-treat 
principle. We compared continuous variables using the two-
sample t-test or Wilcoxon rank-sum test and categorical vari-
ables using the χ2 test or Fisher’s exact test. All statistical analy-
ses were performed using SAS version 9.4 (SAS Institute, Inc., 
Cary, NC, USA). p values <0.05 were considered statistically 
significant. 
Ethical approval
Ethical approval was obtained from the institutional review 
boards of Dongguk University Ilsan Hospital (reference 2015-
132), Asan Medical Center (reference 2016-0087), Kangbuk 
Samsung Hospital (reference KBSMC 2015-12-017), Samsung 
Medical Center (reference SMC 2015-11-039), and Soonchun-
hyang University Seoul Hospital (reference SCHUH 2015-10-
014). Written informed consent was obtained from all partici-
pants. This study was retrospectively registered at the Clinical 
Research Information Service (CRIS, http://cris.nih.go.kr) in 
Korea on May 9, 2018 (KCT0002855, URL: https://cris.nih.
go.kr/cris/en/search/search_result_st01.jsp?seq=11421). 
RESULTS
A total of 215 eligible women were screened, and 148 women 
were enrolled and underwent randomization. 75 women were 
assigned to the HAase injection group, and 73 women were as-
signed to the control group (Fig. 1). One woman in the control 
group was not evaluated after delivery, because she delivered 
by emergency cesarean section after perineal injection. 
A total of 84 women (56.8%) underwent an episiotomy, and 
13 women (8.8%) had an intact perineum. First-, second-, third-, 
and fourth-degree lacerations were observed in 34 women 
(23.0%), 88 women (59.5%), 11 women (7.4%), and one wom-
an (0.7%), respectively. Maternal variables and newborn out-
comes, including maternal age, gestational age at delivery, 
maternal body mass index (BMI), birth weight, and head cir-
cumference of newborns, were similar in the HAase injection 
and control groups (Table 1). 
We compared perineal lacerations between the HAase in-
jection group and the control group (Table 2). No significant 
differences were found in the degree of perineal laceration be-
tween the groups. Intact perineum was observed in 10.7% of 
the women in the HAase injection group and 6.8% of the wom-
en in the control group. However, the difference therein between 





1–2 hr after delivery
24 hr after delivery
Assessed for eligibility (n=215)
Allocated to HAase injection (n=75)
Received HAase injection (n=75)
Allocated to placebo (n=73)
Received placebo injection (n=73)
Excluded (n=67)
• Not meeting inclusion criteria (n=49)
• Declined to participate (n=14)
• Positive skin test to HAase (n=1)
• Delivery in other hospitals (n=3)
Lost to follow-up (n=0)
Analysed (n=75) Analysed (n=73)
Lost to follow-up (n=0)
Randomized (n=148)
Fig. 1. Flow diagram of trial participants according to the CONSORT statement. HAase, hyaluronidase.
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were also no significant differences in the incidence of severe 
perineal lacerations between the two groups (p=0.498). Even 
when analysis was conducted among women without episiot-
omy, there were no statistically significant differences in the de-
grees of perineal laceration between the two groups (p=0.574).
We compared perineal edema at 1 hour and 24 hours after 
vaginal delivery between the HAase injection and control 
groups (Table 3). The women who received HAase injections 
showed significantly improved perineal edema at 24 hours. 
compared to women in the control group who received a pla-
cebo (p=0.008). 
We compared the rates and types of episiotomy between the 
HAase injection and the control groups (Table 4). Episiotomy 
was more frequently performed in the control group than in 
the HAase injection group (61.6% vs. 53.3%, p=0.323, respec-
tively); however, the difference was not statistically significant. 
There was also no significant difference in the types of episiot-
omy between the two groups (p=0.176).  
Neither group reported serious adverse events. However, 
mild adverse events were reported in two women in the HAase 
injection group: One woman complained of fever after delivery, 
but recovered before discharge from the hospital. We confirmed 
that the fever was not related to HAase. The other woman com-
plained of perineal pain at the injection site, but recovered be-
fore discharge from the hospital. Other mild adverse events, in-
cluding changes in blood pressure, pulse rate, white blood cell 
count, and platelet count, were observed, although the differ-
ences between the two groups were not significant.






Maternal age (yr) 31.3±3.0 31.9±2.9 0.225
≥35 yr 8 (10.7) 15 (20.5) 0.115
Gestational age at delivery (wk) 39.8±1.0 39.6±1.1 0.198
Maternal BMI (kg/m2) 20.9±3.5 20.5±3.7 0.425
Obesity (BMI ≥25 kg/m2) 5 (6.7) 4 (5.5) 0.851
Pre-existing medical conditions* 13 (17.3) 12 (16.4) 0.172
Duration of the second stage
   of labor (min)
73.3±71.6 65.0±65.5 0.462
Birth weight (kg)   3.2±0.4 3.2±0.3 0.371
Neonatal head circumference (cm) 34.0±1.2 33.9±1.2 0.389
Apgar score <7 at 5 min 2 (2.7) 0 (0.0) 0.495
HAase, hyaluronidase; BMI, body mass index.
Data are presented as a mean±standard deviation or n (%) unless otherwise 
indicated.
*Pre-existing medical conditions include underlying diseases, such as mater-
nal hypertension, diabetes, and hypothyroidism, or diseases during pregnan-
cy, such as hepatitis, nephritis, and pneumonia.
Table 2. Comparison of Perineal Lacerations between the Group Treat-







Intact perineum 8 (10.7) 5 (6.8) 0.422†
1st-degree laceration 14 (18.7) 20 (27.4)
2nd-degree laceration 48 (64.0) 40 (54.8)
3rd-degree laceration 5 (6.7) 6 (8.2)
4th-degree laceration 0 (0.0) 1 (1.4)
Severe perineal laceration* 5 (6.7) 7 (9.6) 0.498‡
No episiotomy 35 27
Intact perineum 2 (5.7) 0 (0.0) 0.574†
1st-degree laceration 8 (22.9) 6 (22.2)
2nd-degree laceration 22 (62.9) 18 (66.7)
3rd-degree laceration 3 (8.6) 2 (7.4)
4th-degree laceration 0 (0.0) 1 (3.7)
Severe perineal laceration* 3 (8.6) 3 (11.1) 0.737‡
HAase, hyaluronidase.
Data are presented as n (%) unless otherwise indicated. The control group 
had data missing from one woman due to an emergency cesarean delivery.
*Severe laceration was defined as a 3rd-/4th-degree laceration; †Greater than 
or equal to first-degree; ‡Severe perineal lacerations were compared using χ2 
test and Fisher’s exact test.
Table 3. Comparison of Degrees of Perineal Edema between the Group Treated with Hyaluronidase Injections and the Control Group
HAase (n=75) Control (n=73)
p value
PP 1 h PP 24 h PP 1 h PP 24 h
Grade 0.787*/0.063†
Grade 0 5 (6.7) 13 (17.3) 9 (12.3) 8 (11.0)
Grade 1 40 (53.3) 53 (70.7) 32 (43.8) 45 (61.6)
Grade 2 26 (34.7) 6 (8.0) 27 (37.0) 17 (23.3)
Grade 3 3 (4.0) 3 (4.0) 3 (4.1) 2 (2.7)
Grade 4 1 (1.3) 0 (0.0) 1 (1.4) 0 (0.0)
Interval change during 24 h 0.008
No change 44 (58.7) 53 (72.6)
Get better 31 (41.3) 16 (21.9)
Get worse 0 (0.0) 3 (4.1)
HAase, hyaluronidase; PP 1 h, postpartum 1 hour; PP 24 h, postpartum 24 hours.
Data are presented as n (%) unless otherwise indicated. The control group had data missing from one woman due to an emergency cesarean delivery.
p value for *PP 1 h and †PP 24 h.
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DISCUSSION
Perineal trauma after vaginal delivery, especially third- and 
fourth-degree lacerations, can result in substantial morbidities 
that negatively affect a mother’s quality of life. HAase was used 
during childbirth in the 1950s and 1960s to prevent perineal 
trauma, but was gradually replaced with episiotomy. However, 
many reports have demonstrated that an episiotomy is a risk 
factor for perineal trauma.27 Therefore, the utilization of HAase 
injections into the perineum during labor to prevent perineal 
trauma and to decrease the frequency of episiotomies is im-
portant and is the focus of our study. In our study, there were 
no significant differences in the frequencies of perineal lacer-
ations and episiotomy, although perineal edema was signifi-
cantly improved in the HAase injection group, compared to 
the control group.  
There are several possible reasons for the observed lack of 
difference in the incidences of severe perineal lacerations and 
episiotomy between HAase and control groups despite a low-
er rate of severe perineal lacerations and episiotomy in the 
HAase injection group. Several studies have reported a reduc-
tion of perineal trauma using HAase injections; however, 
most of these studies are case series, and the number of stud-
ies was small.15,23,28 Randomized controlled trials have found 
no statistically significant differences in severe perineal out-
comes between women who received perineal HAase injec-
tions and those who received placebo injections15,24,28; howev-
er, the women who received perineal HAase injections during 
the second stage of labor had a lower incidence of perineal 
laceration.15,28 Notwithstanding, the techniques used, the tim-
ing of the injections, and the doses of HAase administered var-
ied in each study, which makes it difficult to compare results 
among the studies. The HAase injections in our study did not 
prevent severe perineal trauma, which may have been the re-
sult of an inadequate drug effect duration or drug dosage. We 
used 5000 IU of HAase within 1 hour within fetal expulsion 
through the vagina. However, it may not have allowed enough 
time for HAase to soften and relax the perineal tissue and in-
crease tissue elasticity. In addition, the low incidence in severe 
perineal lacerations between the HAase injection and control 
groups may explain the lack of difference. It is also possible that 
HAase has no effect on perineal tissue elasticity or that local 
infiltration may make the perineum thicker and may interfere 
with perineal elasticity.
HAase injections in our study were found to be effective in 
the reduction and recovery of perineal edema during the first 
24 hours after delivery. Perineal edema is associated with per-
ineal pain and postpartum discomfort after vaginal delivery. 
Rapid recovery from perineal edema allows for the resumption 
of maternal activities of daily living, such as lying down, sitting, 
walking, infant care, breastfeeding, and urination.4,29 Our study 
showed that a high percentage of women in the HAase injec-
tion group had improved perineal edema at 24 hours, which 
suggests that HAase injections improve tissue diffusion and the 
resorption rate of excess fluid. 
In our study, episiotomy was performed slightly less in the 
HAase injection group than in the control group, although the 
difference was not statistically significant. Among women with 
episiotomies, right mediolateral episiotomy was performed 
more frequently in both groups. Since episiotomy is known to 
be a risk factor for severe perineal laceration, many research-
ers have recommended selective episiotomy during vaginal 
delivery. The type of episiotomy can affect the incidence of se-
vere perineal lacerations. As for perineal edema, although 
there are few studies about the relationship between the types 
of episiotomy and perineal edema and HAase injections, the 
performance of episiotomy or types of episiotomy could affect 
the degree of perineal edema and recovery. In this study, we 
performed selective episiotomy, which was performed when 
it was indicated for reducing the confounding effect of routine 
episiotomy to perineal trauma. Further study is needed to 
identify the association between HAase injections and episiot-
omy (performance and type) and perineal laceration or edema 
after delivery. No HAase injection-related severe complica-
tions in the mothers and newborns were observed, which sug-
gests that HAase injections during labor are safe. 
The strength of our study is its double-blind, placebo-con-
trolled, randomized design. As a limitation, our study was a 
multi-center study, which can introduce measurement bias. 
Further research with a larger sample cohort is recommended 
to elucidate the appropriate dose of HAase and the optimal in-
jection time to prevent perineal lacerations during vaginal de-
livery. 
In conclusion, although there were no significant differenc-
es in the frequencies of severe perineal lacerations, perineal 
HAase injections during delivery in nulliparous women sig-
nificantly reduced perineal edema, compared to the placebo 
group, and are safe for both the mother and fetus.
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Table 4. Comparison of Rates and Types of Episiotomy between the 
Group Treated with Hyaluronidase Injections and the Control Group
HAase (n=75) Placebo (n=73) p value
No episiotomy 35 (46.7) 28 (38.4) 0.323*
Episiotomy 40 (53.3) 45 (61.6) 0.176†
RML 22 (29.3) 32 (43.8)
Median 18 (24.0) 13 (17.8)
HAase, hyaluronidase; RML, right mediolateral.
Data are presented as n (%) unless otherwise indicated. 
*The incidences of episiotomy and no episiotomy; †The types of episiotomies 
were compared using χ2 test and Fisher’s exact test.
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